<DOC>
	<DOCNO>NCT02386761</DOCNO>
	<brief_summary>A phase I randomise , double-blind , placebo-controlled study single repeat ascend dos healthy volunteer investigate safety , tolerability pharmacokinetics inhale chf 6001 .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Inhaled CHF6001</brief_title>
	<detailed_description>To assess safety tolerability single repeat ascend dos CHF 6001 healthy volunteer investigate pharmacokinetic ( PK ) profile CHF 6001 metabolites CHF 5956 CHF 6095 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main Inclusion Subject 's write informed consent obtain prior studyrelated procedure Male female Caucasian healthy volunteer age 1855 year inclusive Vital sign : Subjects age 1845 : Diastolic BP 4090 , Systolic BP 90140 Subjects age 4555 : Diastolic BP 4090 , Systolic BP 90150 ( mean three measure perform least 5 minute rest ) ; check screening visit Day 1 12lead digitise Electrocardiogram ( 12lead ECG ) consider normal ( 40≤Heart rate≤110bpm,120 m ≤ PR ≤ 210 m , QRS ≤ 120 m , QTcF ≤ 450 m male ≤ 470ms female ) check screening visit Day 1 Lung function measurement within normal limit : FEV1 &gt; 80 % predict normal value ( accord Global Lung Function Initiative , ERS Task Force Lung Function Reference Values ( 1,2 ) ) FEV1/FVC ratio &gt; 0.70 Main Exclusion : Pregnant lactate woman Clinically significant cardiac abnormality Any clinically relevant abnormal laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>